BioSpace News Archive

LGC announced the acquisition of a majority stake in Toronto Research Chemicals, a leading manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a highly diversified global customer base across the pharmaceutical, applied and research sectors.

Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC development of innovative biologics, is pleased to announce the establishment of its 3D Advisory Board.

An article published in Experimental Biology and Medicine describes a new drug discovery model for mantle cell lymphoma, a deadly subtype of non-Hodgkin’s lymphoma.

AgriMetis, LLC is pleased to announce that Dr. Andrew Plant joined the AgriMetis team as Chief Technology Officer (CTO) in July 2019.

An article published in Experimental Biology and Medicine describes a new class of kinase inhibitors.

Pharming Group N.V. announced it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome.

Pulmocide Ltd is pleased to announce that in vitro data published in the Journal of Antimicrobial Chemotherapy highlight the potential of its novel antifungal candidate PC945 in the treatment of Candida auris.

Adrenomed AG, the vascular integrity company, announced its participation at four upcoming conferences in Europe.

Ultragenyx Pharmaceutical Inc. announced that Tom Kassberg, the company’s Chief Business Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 1:20 PM ET in New York, NY.